There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 15.
15. For regulation 21 (amendment of regulation 26 (general power to suspend, revoke or vary licences)) substitute—U.K.
“21. For regulation 26(5)(a) substitute—
“(a)that the holder of the manufacturer's licence has manufactured or assembled medicinal products to the order of a person who holds—
(i)in the case of a product for sale or supply in Great Britain, a UKMA(GB), a UKMA(UK), a COR(GB), a COR(UK), a THR(GB) or a THR(UK) (an “authorisation”), or
(ii)in the case of a product for sale or supply in Northern Ireland, a UKMA(NI), a UKMA(UK), a COR(NI), a COR(UK), a THR(NI) or a THR(UK), an EU marketing authorisation or an Article 126a authorisation (an “authorisation”),
and has habitually failed to comply with the provisions of that authorisation; or”.”.
Commencement Information
I1Sch. 2 para. 15 in force at 31.12.2020 immediately before IP completion day, see reg. 1
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
